arrow
A

Anna Turkova

university college london
H指数:29
被引数:2,331

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trial

多替拉韦作为HIV感染儿童的初始或二线治疗方案:ODYSSEY随机试验240周的随访结果

2026-05-050
OA
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial

人类免疫缺陷病毒感染者儿童在ODYSSEY试验中开始一线抗逆转录病毒治疗后治疗失败的预测因素

2026-04-100
OA
Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis

异烟肼在儿童结核病中的疗效:一项个体参与者数据Meta分析

2026-03-011
PRE
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

每日一次的达芦那韦/拉米夫定固定剂量制剂在HIV感染者儿童中的应用:一项在开放标签、多中心、随机、非劣效性D3/PENTA 21试验中嵌套的药代动力学和安全性的子研究

2025-09-260
PREAI
Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With Human Immunodeficiency Virus (HIV) on Dolutegravir in Europe and Thailand

病毒抑制、病毒学失败及安全性结局:欧洲和泰国人类免疫缺陷病毒(HIV)感染儿童和青少年使用Dolutegravir的研究

2025-07-010
OAAI
Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial

SHINE缩短结核病治疗疗程试验中用于儿童胸部X线片分类的方法与流程

2024-11-010
PRE
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients
2024-09-030
OA
Optimising second line anchor drug options for children with HIV in Africa: 96 week results of the CHAPAS-4 randomised trial
2023-12-170
OA
Standards for clinical trials for treating TB
2023-12-013
OAAI
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
2023-10-010
OAAI